• Biome records $78k EBITDA for Q4 and expects EBITDA to exceed $900k for FY25
• Biome delivers record monthly, quarterly and annual sales revenue, up 50%, 33% and 41% respectively
• Biome expects to report its first full-year net profit and gross margin of 61% for FY25

Biome Australia Limited (ASX: BIO) is pleased to provide its Appendix 4C and Activity Report for the quarter ended 30 June 2025. Biome recorded positive EBITDA of $78k for the June quarter (Q4FY25) and expects EBITDA to exceed $900k for the full FY25. The company delivered record monthly, quarterly and annual sales revenue, with June sales reaching $2.1m (up 50% vs PCP), Q4 sales of $5m (up 33% vs PCP), and annual sales of $18.4m (up 41% vs PCP). Cash receipts for the quarter were $3.7m, up 14% vs PCP. Biome made strategic investments in new product launches, inventory build, and international market expansion during the quarter, leading to a net operating cash outflow of $485k. However, the company maintained a cash balance of $2.75m at 30 June 2025 and expects to report its first full-year net profit for FY25 with a gross margin of 61%.

Biome expects to report EBITDA exceeding $900k and gross margin of 61% for the full FY25.

Biome expects Q1 FY26 to be another new record for sales revenue, supported by the launch of its new Activated Therapeutics range and new Activated Probiotics product innovations, as well as the expansion into international markets.